Date: 2015-03-26
Type of information: Opening of new premises
Compound: SPR Center of Excellence
Company: Inventiva (France) SensiQ Technologies (USA - OK)
Therapeutic area: Technology - Services
Type agreement: opening of new premises
Action mechanism:
Disease:
Details:
- • On February 9, 2015, SensiQ, a leader in surface plasmon resonance (SPR) technologies and Inventiva, a French drug discovery company focused on therapeutic approaches involving transcription factors and epigenetic targets, announced the launch of a European Center of Excellence in SPR technologies, using SensiQ® Pioneer Fragment Edition (Pioneer FE) instrumentation. The SPR Center of Excellence is based in Dijon, France. Inventiva’s existing pharmaceutical discovery platform will now include SensiQ SPR technology, which strengthens Inventiva’s current service offering. The new Center also allows SensiQ to offer prospective customers on-site demonstrations at Inventiva’s offices. Inventiva’s entire team will benefit from the extensive SPR experience from the SensiQ dedicated support staff.
- Inventiva is focused on therapeutic approaches involving transcription factors and epigenetic targets (particularly the HKMT family) to discover innovative treatments for cancer, fibrosis, immuno-inflammatory diseases and Parkinson’s disease. The company’s business strategy is to engage in proprietary research programs and secure drug discovery partnerships with pharmaceutical groups. It also offers a full range of research services. These draw on its extensive technology platform, a proprietary library of 240,000 compounds and a fibrosis platform. Inventiva also has expertise in nuclear receptors, transcription factors and epigenetic modulation. Over 100 employees are based at its research center in Daix, near Dijon (France).
Financial terms:
Latest news:
Is general: Yes
